Pharmacycle
Turnover is estimated at about €110,000, probably between €40,000 and €240,000. The micro format does not state turnover.
Balance sheet
balance sheet total €41,191 on 31-12-2025in euro
in euro
Position in the sector
70.8%
Higher than 81% of the 25,459 companies filing micro accounts in retail trade (NACE 47) in 2025.
2.89
Higher than 76% of the 24,457 companies filing micro accounts in retail trade (NACE 47) in 2025.
13.7%
Higher than 77% of the 24,646 companies filing micro accounts in retail trade (NACE 47) in 2025.
Net result: middle half · Equity: middle half · Balance sheet total: bottom quarter · Working capital: middle half
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 20187 months |
|---|---|---|---|---|---|---|---|---|---|
| 10,240 | 55,478 | 27,018 | 14,658 | 6,018 | 12,088 | 19,001 | 16,482 | ||
| 8,681 | 41,984 | 20,168 | 10,841 | 4,940 | 10,298 | 14,141 | 12,058 | ||
| 0 | 3,225 | 5,039 | 0 | 4,215 | 7,414 | 3,019 | 4,147 | ||
| -9,283 | -18,463 | 5,844 | 5,415 | 3 | -7,151 | -2,210 | - | ||
| 22,704 | 20,591 | 33,583 | 26,567 | 17,943 | 16,482 | 29,821 | 19,511 | ||
| 70.8% | 31.9% | 64.5% | 88.9% | 77.4% | 74.8% | 83.8% | 63.6% | ||
| 2.89 | 1.34 | 2.69 | 7.43 | 3.81 | 2.88 | 5.50 | 2.49 | ||
| 0.41 | 2.13 | 0.55 | 0.12 | 0.29 | 0.34 | 0.19 | 0.57 | ||
| 19.3% | 133.0% | 41.5% | 22.9% | 7.1% | 30.7% | 35.7% | 49.2% | ||
| 13.7% | 42.5% | 26.8% | 20.4% | 5.5% | 22.9% | 29.9% | 31.3% | ||
| 35.37 | over 100 | 78.86 | 88.29 | 22.46 | - | - | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 20187 months |
|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||||
20/58 |
41,191 | 91,392 | 62,909 | 38,435 | 35,074 | 34,798 | 40,889 | 35,916 | |
21/28 |
6,473 | 9,514 | 9,469 | 7,739 | 10,748 | 9,539 | 4,448 | 3,341 | |
22/27 |
6,473 | 9,514 | 9,469 | 7,739 | 10,748 | 9,539 | 4,448 | 3,341 | |
23 |
1,606 | 1,785 | - | - | - | - | - | - | |
24 |
4,868 | 7,730 | 9,469 | 7,739 | 10,748 | 9,539 | 4,448 | 3,341 | |
29/58 |
34,718 | 81,878 | 53,440 | 30,696 | 24,325 | 25,259 | 36,441 | 32,575 | |
29 |
- | - | - | - | - | 2,901 | - | - | |
291 |
- | - | - | - | - | 2,901 | - | - | |
40/41 |
18,288 | 18,056 | 22,252 | 5,835 | 5,007 | 3,042 | 9,984 | 3,972 | |
40 |
10,532 | 8,730 | 11,104 | 1,411 | 2,639 | - | 7,546 | 3,972 | |
41 |
7,756 | 9,326 | 11,148 | 4,424 | 2,367 | 3,042 | 2,437 | - | |
50/53 |
13,077 | 51,233 | - | - | - | - | - | - | |
54/58 |
2,731 | 12,014 | 30,476 | 24,632 | 19,217 | 19,215 | 26,365 | 28,576 | |
490/1 |
622 | 576 | 712 | 229 | 101 | 101 | 92 | 27 | |
| Balance sheet: equity and liabilities | |||||||||
10/49 |
41,191 | 91,392 | 62,909 | 38,435 | 35,074 | 34,798 | 40,889 | 35,916 | |
10/15 |
29,178 | 29,178 | 40,594 | 34,187 | 27,156 | 26,021 | 34,269 | 22,852 | |
10/11 |
2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 12,400 | 12,400 | |
100 |
- | - | - | - | - | - | 18,600 | 12,400 | |
101 |
- | - | - | - | - | - | 6,200 | - | |
13 |
27,178 | 27,178 | 38,594 | 32,187 | 25,156 | 24,021 | 21,869 | 10,452 | |
130 |
- | - | - | - | - | - | 1,240 | 1,240 | |
133 |
27,178 | 27,178 | 38,594 | 32,187 | 25,156 | 24,021 | 20,629 | 9,212 | |
17/49 |
12,013 | 62,214 | 22,315 | 4,247 | 7,918 | 8,777 | 6,620 | 13,063 | |
17 |
- | 928 | 2,458 | 119 | 1,535 | - | - | - | |
170/4 |
- | 928 | 2,458 | 119 | 1,535 | - | - | - | |
42/48 |
12,013 | 61,287 | 19,857 | 4,129 | 6,383 | 8,777 | 6,620 | 13,063 | |
42 |
928 | 1,530 | 1,575 | 1,416 | 1,404 | - | - | - | |
44 |
303 | 762 | 1,865 | 910 | 2,991 | 2,496 | 3,098 | 5,284 | |
440/4 |
303 | 762 | 1,865 | 910 | 2,991 | 2,496 | 3,098 | 5,284 | |
46 |
- | - | 117 | - | - | - | - | - | |
45 |
5,143 | 8,774 | 5,848 | 1,003 | 1,188 | 457 | 2,710 | 6,611 | |
450/3 |
5,143 | 8,774 | 5,848 | 1,003 | 1,188 | 457 | 37 | 4,420 | |
454/9 |
- | - | - | - | - | - | 2,673 | 2,191 | |
47/48 |
5,640 | 50,220 | 10,452 | 800 | 800 | 5,823 | 812 | 1,168 | |
| Income statement | |||||||||
76A |
- | - | 97 | - | - | - | - | - | |
9900 |
10,640 | 55,865 | 27,402 | 15,006 | 6,366 | 12,436 | 19,348 | 16,829 | |
630 |
3,041 | 3,180 | 3,309 | 3,009 | 3,006 | 2,323 | 1,913 | 806 | |
640/8 |
400 | 387 | 384 | 348 | 348 | 348 | 348 | 348 | |
9901 |
7,199 | 52,298 | 23,709 | 11,649 | 3,013 | 9,766 | 17,088 | 15,676 | |
75/76B |
540 | 817 | 434 | 138 | 93 | 258 | 53 | - | |
75 |
540 | 817 | 434 | 138 | 93 | 258 | 53 | - | |
65/66B |
290 | 206 | 343 | 166 | 268 | 54 | 52 | 71 | |
65 |
290 | 206 | 343 | 166 | 268 | 54 | 52 | 71 | |
9903 |
7,450 | 52,909 | 23,800 | 11,620 | 2,837 | 9,970 | 17,089 | 15,604 | |
67/77 |
1,810 | 14,105 | 6,941 | 3,789 | 903 | 1,994 | 4,860 | 4,352 | |
9904 |
5,640 | 38,804 | 16,859 | 7,831 | 1,935 | 7,976 | 12,228 | 11,252 | |
9905 |
5,640 | 38,804 | 16,859 | 7,831 | 1,935 | 7,976 | 12,228 | 11,252 | |
| Appropriation of the result | |||||||||
9906 |
5,640 | 38,804 | 16,859 | 7,831 | 1,935 | 7,976 | 12,228 | 11,252 | |
791/2 |
- | 11,416 | 10,452 | - | - | - | - | - | |
691/2 |
- | - | 16,859 | 7,031 | 1,135 | 2,152 | 11,416 | 10,452 | |
6920 |
- | - | - | - | - | - | - | 1,240 | |
6921 |
- | - | 16,859 | 7,031 | 1,135 | 2,152 | 11,416 | 9,212 | |
694/7 |
5,640 | 50,220 | 10,452 | 800 | 800 | 5,823 | 812 | 800 | |
694 |
5,640 | 50,220 | 10,452 | 800 | 800 | 5,823 | 812 | 800 | |
| Document | |||||||||
The full notes are in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 29-05-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 29-05-2026 | 2026-00125468 | |
| 31-12-2024 | micro format | 21-02-2025 | 2025-00037296 | |
| 31-12-2023 | micro format | 04-06-2024 | 2024-00110491 | |
| 31-12-2022 | micro format | 30-05-2023 | 2023-00098335 | |
| 31-12-2021 | micro format | 13-06-2022 | 2022-20058395 | |
| 31-12-2020 | micro format | 03-06-2021 | 2021-16800137 | |
| 31-12-2019 | micro format | 22-07-2020 | 2020-32400353 | |
| 31-12-2018 | micro format | 01-07-2019 | 2019-25200073 |
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | - | €3,225 | €5,039 | - | €4,215 |
| €3,041 | €3,180 | €3,309 | €3,009 | €3,006 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on Pharmacycle
The operating result for 2025 is 86% lower than in 2024 and the lowest since 2021.
Debt's share of the balance-sheet total falls from 68.1% to 29.2%. Debt is lower.